In a remarkable milestone for medical science, the realm of drug discovery has witnessed a groundbreaking leap as the first-ever drug fully generated by AI enters clinical trials with human patients.
Insilico Medicine has developed the first fully generative AI drug, INS018_055, for the treatment of idiopathic pulmonary fibrosis.
IPF is a chronic disease causing scarring in the lungs, and it currently affects around 100,000 people in the U.S.
The analysis A.I. (PandaOmics) and the generative A.I. (Chemistry42) contributed to the process in the following ways:
The AI analyzed scientific data from clinical trials and public databases. to detect disease-causing targets .
Then, a generative AI program, was used to design new molecules with specific characteristics that could act on the specific target.
AI ranked the molecules based on their likelihood of success. INS018_055, the selected molecule, showed the most promising activity.
The drug has now entered Phase II of human clinical trials. If all goes well, further studies with larger cohorts will follow.
The research team states that the drug will be approved and available for patients within the next few years, providing new hope for those suffering from IPF.